Sutro Biopharma Stock Price, News & Analysis

Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.

Sutro Biopharma announced two key presentations at the 2025 AACR Annual Meeting in Chicago, showcasing their advances in antibody drug conjugates (ADCs). The company will present data on two significant developments:

• STRO-004: A novel exatecan Tissue Factor ADC showing strong anti-tumor activity and favorable safety in preclinical studies. Single-dose treatments demonstrated promising response rates in Tissue Factor-positive patient models across multiple cancers. The company plans to begin human trials later this year.
• XpressCF+® Platform: Their proprietary cell-free platform enables creation of dual-payload ADCs with higher drug-to-antibody ratios and site-selective conjugation of two linker payloads.

CEO Jane Chung highlighted that STRO-004 achieved notable disease control rates in preclinical studies. The presentations will take place on April 28, with Dr. Alice Yam presenting on STRO-004 and Dr. Gang Yin discussing dual-payload ADC development. The research demonstrates Sutro's leadership in developing next-generation cancer treatments.

Sutro Biopharma (NASDAQ: STRO) presented expanded data from the dose-optimization portion of the REFRαME-O1 trial for luveltamab tazevibulin (luvelta) in platinum resistant ovarian cancer at SGO 2025. The study demonstrated:

At the optimized dose of 5.2 mg/kg + G-CSF (followed by 4.3 mg/kg), luvelta achieved:

• 32% overall response rate (ORR) and 96% disease control rate (DCR), compared to 13.8% ORR and 69% DCR at 4.3 mg/kg
• Consistent clinical activity across FRα expression levels ≥25%
• 30.8% ORR and 100% DCR for positive staining 2+ ≥75%
• 33.3% ORR and 91.7% DCR for PS2+ <75%

The safety profile remained consistent across dosing groups, with manageable neutropenia. However, Sutro announced it is deprioritizing luvelta's development across all indications and is seeking out-licensing opportunities.

Sutro Biopharma (NASDAQ: STRO) has reported its full year 2024 financial results, announcing a strategic portfolio review that prioritizes wholly-owned next-generation ADC programs. The company's financial position shows $316.9 million in cash, cash equivalents, and marketable securities as of December 31, 2024, projecting a cash runway into at least Q4 2026.

Key financial metrics include:

• Revenue decreased to $62.0 million in 2024 from $153.7 million in 2023
• Total operating expenses increased to $300.5 million in 2024 from $243.0 million in 2023
• Research and development expenses were $252.0 million
• General and administrative expenses totaled $48.5 million

The restructuring plan is expected to require $40 to $45 million in cash payments, but subsequent cost reductions and refocused clinical development priorities are anticipated to support the company's operations through Q4 2026.

Sutro Biopharma (NASDAQ: STRO) has announced a major strategic portfolio restructuring, focusing on its next-generation ADC pipeline development. The company will prioritize three wholly-owned preclinical programs, with STRO-004, a Tissue Factor ADC, expected to enter clinical trials in H2 2025.

Key changes include:

• Deprioritizing luveltamab tazevibulin development while seeking partnership opportunities
• Reducing workforce by nearly 50%
• Exiting internal GMP manufacturing facility by year-end 2025
• Leadership transition: Jane Chung replacing Bill Newell as CEO

The company reported $316.9 million in cash and equivalents as of December 31, 2024, with runway expected into Q4 2026. Restructuring costs are estimated at $40-45 million. The pipeline includes three planned INDs over the next three years: STRO-004 (H2 2025), STRO-006 (2026), and a dual-payload ADC (2027).

Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in site-specific and novel-format antibody drug conjugates (ADCs), has announced its participation in the TD Cowen 45th Annual Health Care Conference. The conference is scheduled for March 3-5, 2025, in Boston, MA.

The company's management will deliver a presentation, which will be made available through the News & Events page in the Investor Relations section of Sutro's website (www.sutrobio.com). Interested parties can access an archived replay of the presentation for a minimum of 30 days following the event.

Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bill Newell, the company's Chief Executive Officer, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.

The presentation will be available to view through the News & Events page in the Investor Relations section of Sutro's website at www.sutrobio.com. An archived version of the presentation will remain accessible for a minimum of 30 days following the event.

Sutro Biopharma (STRO) and Boehringer Ingelheim BioXcellence™ have successfully scaled up Sutro's proprietary cell-free expression technology to commercial scale manufacturing. The collaboration achieved production of luveltamab tazevibulin (luvelta), Sutro's antibody-drug conjugate (ADC) for ovarian cancer treatment, at 4,500L scale in Boehringer's Vienna facility.

The breakthrough represents an industry milestone, marking the first successful transition from small-scale to large-scale GMP production using Sutro's cell-free protein synthesis platform. All manufactured batches met the required quality criteria for clinical studies. The platform's unique advantage lies in its modular approach, utilizing non-natural amino acids for site-specific protein conjugation, potentially offering improved safety and efficacy profiles compared to traditional ADC production methods.

This achievement validates the commercial viability of Sutro's technology and can be applied to their pipeline of next-generation ADCs targeting various cancers. Sutro is actively seeking business development partners to advance their technology platform and product pipeline.